Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noboru Yamamoto

Showing results (11-20 of 436) with videos related to

Pageof 44
Sort By:
Clinical Therapeutics|January 18, 2016
Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung CancerHiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe, et al.
Japanese Journal of Clinical Oncology|May 1, 2010
A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumorsYasuhito Fujisaka, Yasuhide Yamada, Noboru Yamamoto, et al.
Modern Rheumatology|April 8, 2015
Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapyNoboru Yamamoto, Kaoru Sato, Takayuki Hoshina, et al.
Journal of the American Chemical Society|September 16, 2004
Immunological consequences of methamphetamine protein glycationTobin J Dickerson, Noboru Yamamoto, Diana I Ruiz, et al.
Japanese Journal of Clinical Oncology|November 11, 2006
Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumorsYasuhito Fujisaka, Atsushi Horiike, Toshio Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2008
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapyIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Frontiers in Medicine|October 9, 2024
Regional diversity in drug-induced lung diseases among the USA, European Union, and JapanJun Sato, Ryo Sadachi, Takafumi Koyama, et al.
Frontiers in Oncology|September 12, 2022
Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and ChinaTakaaki Mizuno, Yuki Katsuya, Jun Sato, et al.
Investigational New Drugs|August 8, 2018
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015Kota Itahashi, Toshio Shimizu, Takafumi Koyama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2009
Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV diseaseIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Pageof 44

Showing results (11-20 of 436) with videos related to

Sort By:
Pageof 44
Clinical Therapeutics|January 18, 2016
Pharmacokinetics of Weekly Paclitaxel and Feasibility of Dexamethasone Taper in Japanese Patients with Advanced Non-small Cell Lung CancerHiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe, et al.
Japanese Journal of Clinical Oncology|May 1, 2010
A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumorsYasuhito Fujisaka, Yasuhide Yamada, Noboru Yamamoto, et al.
Modern Rheumatology|April 8, 2015
Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapyNoboru Yamamoto, Kaoru Sato, Takayuki Hoshina, et al.
Journal of the American Chemical Society|September 16, 2004
Immunological consequences of methamphetamine protein glycationTobin J Dickerson, Noboru Yamamoto, Diana I Ruiz, et al.
Japanese Journal of Clinical Oncology|November 11, 2006
Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumorsYasuhito Fujisaka, Atsushi Horiike, Toshio Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2008
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapyIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Frontiers in Medicine|October 9, 2024
Regional diversity in drug-induced lung diseases among the USA, European Union, and JapanJun Sato, Ryo Sadachi, Takafumi Koyama, et al.
Frontiers in Oncology|September 12, 2022
Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and ChinaTakaaki Mizuno, Yuki Katsuya, Jun Sato, et al.
Investigational New Drugs|August 8, 2018
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015Kota Itahashi, Toshio Shimizu, Takafumi Koyama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2009
Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV diseaseIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Pageof 44